• Teodor Pelea, Ursula Reuter, Christine Schmidt, Raimondo Laubinger, Robert Siegmund, and Bjoern Wito Walther.
• Department of Neurology, Care Medicine, SRH Zentralklinikum Suhl, Albert-Schweitzer-Strasse 2, 98527, Suhl, Germany.
• J. Neurol. 2021 Apr 1; 268 (4): 1191-1194.

AbstractPresented herein is a severe case of SARS-CoV-2 associated Guillain-Barré syndrome (GBS), showing only slight improvement despite adequate therapy. To date, only few cases of GBS associated with this infection have been described. This case report summarizes the insights gain so far to GBS with this antecedent trigger. So far, attention has mostly focused on complications of the CNS involvement. Taking into account that GBS can cause a considerable impairment of the respiratory system, clinicians dealing with SARS-CoV-2 positive-tested patients should pay attention to symptoms of the peripheral nervous system. As far as we know from this reported case and the review of the current literature, there seems to be no association with antiganglioside antibodies or a positive SARS-CoV-2 RT-PCR in CSF. An obvious frequent occurrence of a bilateral facial weakness or bilateral peripheral facial diplegia should be emphasized.

12 keywords...

hide…